ClinicalTrials.gg
RecruitingNCT05595668EMPATHUpdated Jul 30, 2025

Engaging Mobile Prism Adaptation Treatment at Home

An interventional study of Prism Adaptation - 15-degree prism goggles and Prism Adaptation - 5-degree prism goggles in Spatial Neglect, sponsored by Nova Scotia Health Authority. Recruiting at 4 sites in Canada. Per ClinicalTrials.gov, last updated 2025-07-30.

Sponsored by Nova Scotia Health Authority · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Stroke by Nova Scotia Health Authority — 5 open to participants now, 5 under way, none of them phase 3. Stroke · Nova Scotia Health Authority.

Planned enrollment
Largest of 11
80 · median 14
Started
2023
the only one that year
No phase
10 of 14
4 open now
Registered
10th of 14
by date

Among the 14 studies in Stroke by Nova Scotia Health Authority, this one has the largest planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 10 with no phase, and was the 10th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

5 of the 14 studies in Stroke by Nova Scotia Health Authority are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Stroke by Nova Scotia Health Authority, or all of them as a file.
02

Study summary

Spatial neglect is a common disorder after stroke which leads to problems with noticing or responding to information from the left side of the body or space. This condition has been linked to reduced independence in a wide range of daily life activities including eating, dressing, and mobility. Despite its high prevalence in stroke patients, there is currently no standard of care for spatial neglect. Prism adaptation (PA) is a promising treatment, however, there are limitations to using PA in standard clinical care as it requires daily exposure for at least two weeks, yet access to equipment and supervision is limited. To solve this problem, the investigators have developed a new game-like PA treatment (Peg-the-Mole, PTM) that can be used at home without the need for daily in person therapist set-up and supervision. In this study the investigators aim to evaluate the feasibility and effectiveness of the gamified and portable PA procedure in an inpatient and home setting, with the hypothesis that the PA procedure will improve patient's neglect symptoms.

Read the detailed description

Spatial neglect is a common debilitating cognitive syndrome after stroke which is characterized by an inability to pay attention or respond to the left side of space. Thus, individuals who face this condition often experience difficulties with mobility, reading, and self-care activities such as eating, dressing, and grooming Individuals who face this condition often experience difficulties with mobility, reading, and self-care activities such as eating, dressing, and grooming which lead to increased assistance needed from a caretaker. Although this syndrome has been linked to poor rehabilitation outcomes and reduced independence in everyday life, there is currently an unmet need for an effective and feasible intervention for the treatment of spatial neglect. The investigators have developed and validated a novel, simple, and gamified computerized prism adaptation (PA) procedure for the treatment of spatial neglect. The goal of the present study is to extend this treatment to iPad administration and to test whether the protocol is feasible and effective in a typical inpatient stroke health care setting and in the home setting. Thus, the purpose of this project is to conduct a randomized, controlled, multi-site clinical trial, comparing the PA method to a placebo control intervention for the treatment of spatial neglect. The investigators will measure short- and longer-term effectiveness in terms of impairment (i.e., does PA improve neglect symptoms over time), impact on activities of daily living (i.e., foes PA improve independence in daily activities). Feasibility will be measured by overall treatment compliance and patient feedback on usability. This novel PA procedure has the potential to improve patient recovery and quality of life after stroke due to its gamified and portable features that promote treatment accessibility and adherence. The results will help determine if the treatment can be used successfully in inpatient and outpatient settings and who is likely to benefit.

A longitudinal, double-blind, randomized controlled design will be used in the present study. Patients will be randomly assigned (with stratification related to neglect severity) to PA with the use of 15-degree rightward deviating goggles (experimental condition) or PA with the use of 5-degree deviating goggles (placebo control condition). Participants will complete 10, 15-minute training sessions over approximately two weeks. These intervention sessions will involve using a novel and game-like iPad-administered PA procedure called Peg-the-Mole (PTM). Participants will complete the intervention sessions in an inpatient setting or in their homes, depending on their predicted length of hospital stay. A hybrid model will be adopted if a patient is discharged before the intervention is complete. Outcome measures will be collected immediately before, immediately after, and one-month post-treatment and compared between conditions.

03

Conditions studied

  • Spatial Neglect

Browse trials for

Keywords

  • Spatial Neglect
  • Prism Adaptation
  • Rehabilitation
  • Stroke
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have experienced a right hemisphere stroke (confirmed by a clinician)
  2. Experience mild to severe symptoms of neglect
  3. Be willing and able to consent to participate
  4. Be medically stable
  5. Have self-reported normal to corrected-to-normal vision
  6. Be able to point to targets presented on a computer screen
  7. Live within a two-hour radius of Halifax

Exclusion criteria

Exclusion Criteria:

Other existing neurological disorders (e.g., dementia, multiple sclerosis, epilepsy).

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Prism adaptation treatment

    Prism Goggles with 15-degree rightward deviating prism lenses will be used to implement prism adaptation treatment, in addition to standard care.

    Behavioral: Prism Adaptation - 15-degree prism goggles

  • Placebo comparator
    Placebo control prism adaptation treatment

    Prism goggles with 5-degree rightward deviating prism lenses will be used to maintain the double-blind methodology.

    Other: Prism Adaptation - 5-degree prism goggles

Interventions

  • BehavioralPrism Adaptation - 15-degree prism goggles

    Patients in the experimental condition will wear prism goggles while completing an iPad-administered aiming task. The prisms will shift the patients' vision 15 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out for ten sessions for 15 minutes a day, over the span of two weeks.

  • OtherPrism Adaptation - 5-degree prism goggles

    5-degree goggles are worn instead of the 15-degree prism goggles, while completing the same tasks as those assigned to the 15-degree condition.

    Also known as: Control condition

06

What researchers measure

Primary outcomes

  1. Test of neglect severity 1

    Change in Behavioural Inattention Test - All conventional subtests (BIT-C)

    Time frame: taken at baseline (immediately before the intervention), immediately after the intervention, and one month after the intervention

  2. Test of neglect severity 2

    Change in after-effects measured by a modified proprioceptive-and-visual straight-ahead outcome task without the use of an occlusion board

    Time frame: measured immediately before and immediately after each intervention session

  3. Test of neglect severity 3

    Change in Behavioural Inattention Test - Select behavioural subtests (BIT-B): Article Reading, Menu Reading, and Picture Scanning

    Time frame: taken at baseline (immediately before the intervention), immediately after the intervention, and one month after the intervention

  4. Test of neglect impact on daily activities

    Change in an Eschenbeck Standardized Activities of Daily Living task: Filling out a Form

    Time frame: taken at baseline (immediately before the intervention), immediately after the intervention, and one month after the intervention

  5. Scale of neglect impact on daily activities

    Change in Halifax Neglect Impact Scale

    Time frame: taken at baseline (immediately before the intervention), immediately after the intervention, and one month after the intervention

  6. Measure of feasibility Measure of feasibility

    Treatment compliance with the intervention schedule daily

    Time frame: logged immediately following each intervention session through training logs

  7. Measure of feasibility 2

    Patient feedback exit questionnaire

    Time frame: collected immediately after the intervention

07

Study locations

3 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 38 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2022
First posted
Oct 27, 2022
StartActual
Sep 15, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jul 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05595668
Responsible party
Anne Sophie Champod (Professor / Affiliated Scientist, Nova Scotia Health Authority) — Principal investigator
First posted
Oct 27, 2022
Start date
Sep 15, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jul 30, 2025

Study contacts

Anne Sophie Champod, PhD
Contact
anne.champod@acadiau.ca
9028176871

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion